

## ERRATUM

In: *Simonsen AB, Sommerlund M, Deleuran M, Mortz CG Johansen JD. Course of Skin Symptoms and Quality of Life in Children Referred for Patch Testing – A Long-term Follow-up Study. Acta Derm Venereol 2015; 95: 206–210* Tables II–IV are incorrect. The changes are **highlighted** in the Tables below.

Table II. *Logistic regression analysis with the outcome "persistent eczema" and different explanatory variables*

Explanatory variables	Persistent eczema <sup>a</sup> % (n/n <sub>total</sub> )	Crude OR <sup>b</sup> (95% CI)	Adjusted OR <sup>b</sup> (95% CI)
<b>Gender</b>			
Male	30.9 (94/304)	1 (ref)	1 (ref)
Female	31.1 (199/639)	1.01 (0.75–1.33)	1.01 (0.74–1.36)
<b>Age, years</b>			
<10	34.6 (27/78)	1 (ref)	1 (ref)
11–15	27.6 (51/185)	0.72 (0.41–1.27)	0.86 (0.48–1.53)
16–20	31.5 (138/438)	0.87 (0.52–1.44)	1.02 (0.60–1.72)
>21	31.8 (77/242)	0.88 (0.51–1.51)	1.22 (0.64–2.32)
<b>Atopic dermatitis</b>			
<b>No</b>	23.5 (114/486)	1 (ref)	1 (ref)
<b>Yes</b>	39.2 (179/457)	2.10 (1.59–2.78)	2.05 (1.54–2.72)*
<b>Contact allergy<sup>c</sup></b>			
<b>No</b>	31.6 (220/696)	1 (ref)	1 (ref)
<b>Yes</b>	29.6 (73/247)	0.91 (0.66–1.25)	0.98 (0.71–1.35)
<b>Follow-up, years</b>			
2–4	33.8 (152/450)	1 (ref)	1 (ref)
5–7	28.2 (78/277)	0.77 (0.55–1.07)	0.74 (0.52–1.06)
8–10	29.2 (63/216)	0.81 (0.57–1.15)	0.72 (0.45–1.13)

\* $p < 0.05$ .

<sup>a</sup> $n = 293$ . <sup>b</sup>Adjusted for all explanatory variables. <sup>c</sup>Positive patch test reaction to at least one allergen.

OR: odds ratio; CI: confidence interval.

Table III. *Predictors of having severely affected life quality. Patients  $\leq 16$  years*

Explanatory variables	All patients		Without atopic dermatitis	
	CDLQI severely affected ( $n = 124$ ) % (n/n <sub>total</sub> )	Crude OR <sup>a</sup> (95% CI)	CDLQI severely affected ( $n = 54$ ) % (n/n <sub>total</sub> )	Crude OR <sup>a</sup> (95% CI)
<b>Gender</b>				
Male	15.8 (9/57)	1 (ref)	12.0 (3/25)	1 (ref)
Female	16.4 (11/67)	1.05 (0.40–2.74)	6.9 (2/29)	0.54 (0.08–3.55)
<b>Age, years</b>				
$\leq 10$	24.4 (12/49)	1 (ref)	12.5 (2/16)	1 (ref)
11–16	10.76 (8/75)	0.37 (0.14–0.98)*	7.9 (3/38)	0.6 (0.09–3.99)
<b>Atopic dermatitis</b>				
<b>No</b>	9.3 (5/54)	1 (ref)		
<b>Yes</b>	21.4 (15/70)	2.67 (0.91–7.90)**		
<b>Contact allergy<sup>b</sup></b>				
<b>No</b>	16.0 (15/94)	1 (ref)	9.8 (4/41)	1 (ref)
<b>Yes</b>	16.7 (5/30)	1.05 (0.35–3.19)	7.7 (1/13)	0.77 (0.08–7.58)
<b>Persistent eczema</b>				
<b>No</b>	7.1 (6/84)	1 (ref)	4.8 (2/42)	1 (ref)
<b>Yes</b>	35.0 (14/40)	7.00 (2.44–20.09)*	25.0 (3/12)	6.67 (0.97–45.92)*

<sup>a</sup>Odds ratios (OR) calculated by  $\chi^2$  testing across subgroups.

<sup>b</sup>At least one positive patch test reaction.

\* $p < 0.05$ , \*\* $p = 0.07$ .

Table IV. Predictors of having severely affected life quality. Patients  $\geq 17$  years

Explanatory variables	All patients		Without atopic dermatitis	
	DLQI severely affected ( $n=452$ ) % ( $n/n_{total}$ )	Crude OR <sup>a</sup> (95% CI)	DLQI severely affected ( $n=198$ ) % ( $n/n_{total}$ )	Crude OR <sup>a</sup> (95% CI)
Gender				
Male	9.5 (11/116)	1 (ref)	6.0 (3/50)	1 (ref)
Female	25.3 (85/336)	3.23 (1.66–6.31)**	22.3 (33/148)	4.50 (1.32–15.38)*
Age, years				
17–21	21.9 (69/315)	1 (ref)	19.1 (26/136)	1 (ref)
$\geq 22$	19.7 (27/137)	0.88 (0.53–1.44)	16.1 (10/62)	0.81 (0.36–1.81)
Atopic dermatitis				
No	18.2 (36/198)	1 (ref)		
Yes	23.6 (60/254)	1.39 (0.88–2.21)		
Contact allergy <sup>b</sup>				
No	21.3 (72/338)	1 (ref)	18.4 (4/41)	1 (ref)
Yes	21.1 (24/114)	0.99 (0.59–1.66)	17.7 (11/62)	0.96 (0.44–2.10)
Persistent eczema				
No	11.8 (32/271)	1 (ref)	7.2 (9/125)	1 (ref)
Yes	35.4 (64/181)	4.09 (2.53–6.59)**	37.0 (27/73)	7.57 (3.31–17.32)**

<sup>a</sup>Odds ratios (OR) calculated by  $\chi^2$  testing across subgroups.

<sup>b</sup>At least one positive patch test reaction.

\* $p < 0.05$ , \*\* $p < 0.001$ .

Table SI. Patients without atopic dermatitis. Logistic regression analysis with the outcome “persistent eczema” and different explanatory variables

Explanatory variables	Persistent eczema <sup>a</sup> % ( $n/n_{total}$ )	Crude OR <sup>b</sup> (95% CI)	Adjusted OR <sup>b</sup> (95% CI)
Gender			
Male	22.7 (35/154)	1 (ref)	1 (ref)
Female	23.8 (79/332)	1.06 (0.67–1.67)	1.04 (0.65–1.65)
Age			
< 10 years	21.9 (7/32)	1 (ref)	1 (ref)
11–15 years	18.9 (20/106)	0.83 (0.32–2.19)	0.88 (0.33–2.33)
16–20 years	26.1 (59/226)	1.26 (0.52–3.07)	1.39 (0.56–3.44)
> 21 years	23.0 (28/122)	1.06 (0.42–2.72)	1.40 (0.49–4.00)
Contact allergy <sup>c</sup>			
No	24.1 (81/336)	1 (ref)	1 (ref)
Yes	22.0 (33/150)	0.89 (0.56–1.41)	0.88 (0.55–1.40)
Follow-up			
2–4 years	26.6 (58/218)	1 (ref)	1 (ref)
5–7 years	20.0 (30/150)	1.28 (0.76–2.18)	0.64 (0.38–1.09)
8–10 years	22.0 (26/118)	0.81 (0.49–1.60)	0.68 (0.36–1.30)

<sup>a</sup> $n=114$ . <sup>b</sup>Adjusted for all explanatory variables. <sup>c</sup>Positive patch test reaction to at least one allergen.

OR: odds ratio; CI: confidence interval.